Financial Times article on Orphan Drugs
14 Aug. 2012This article talks about various issues around rare conditions and the orphan drugs that are needed to treat those conditions.
It deals with the difficulty in diagnosing rare conditions, the costs of drug development, the role of pharma companies, the investment needed, the cost-effectiveness process applied and what European governments and other stake-holders need to do to sustain future availability of such drugs.
Financial Times article – Orphan Diseases
July 24th, 2012
